Hancock Jaffe Laboratories Stock Forecast, Price & News

+0.24 (+4.12 %)
(As of 04/21/2021 03:43 PM ET)
Today's Range
Now: $6.06
50-Day Range
MA: $6.71
52-Week Range
Now: $6.06
Volume826 shs
Average Volume582,420 shs
Market Capitalization$51.53 million
P/E RatioN/A
Dividend YieldN/A
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.
Hancock Jaffe Laboratories logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:HJLI
Phone(949) 261-2900
Year FoundedN/A



Sales & Book Value

Annual Sales$30,000.00
Book Value$1.38 per share


Net Income$-7,630,000.00


Market Cap$51.53 million
Next Earnings Date6/14/2021 (Estimated)
OptionableNot Optionable


First U.S. Patent Issues on Hancock Jaffe VenoValve
April 7, 2021 |
First U.S. Patent Allowed on Hancock Jaffe VenoValve
February 24, 2021 |
Hancock Jaffe Completes $41 Million Public Offering
February 11, 2021 |
Hancock Jaffe Announces Executive Promotions
December 30, 2020 |
See More Headlines


Overall MarketRank

0.46 out of 5 stars

Medical Sector

1689th out of 2,025 stocks

Surgical & Medical Instruments Industry

147th out of 169 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.24 (+4.12 %)
(As of 04/21/2021 03:43 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HJLI News and Ratings via Email

Sign-up to receive the latest news and ratings for HJLI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hancock Jaffe Laboratories (NASDAQ:HJLI) Frequently Asked Questions

Is Hancock Jaffe Laboratories a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hancock Jaffe Laboratories in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Hancock Jaffe Laboratories stock.
View analyst ratings for Hancock Jaffe Laboratories
or view top-rated stocks.

What stocks does MarketBeat like better than Hancock Jaffe Laboratories?

Wall Street analysts have given Hancock Jaffe Laboratories a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hancock Jaffe Laboratories wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 390,100 shares, an increase of 77.4% from the February 28th total of 219,900 shares. Based on an average daily trading volume, of 570,900 shares, the short-interest ratio is currently 0.7 days. Approximately 41.7% of the company's stock are sold short.
View Hancock Jaffe Laboratories' Short Interest

When is Hancock Jaffe Laboratories' next earnings date?

Hancock Jaffe Laboratories is scheduled to release its next quarterly earnings announcement on Monday, June 14th 2021.
View our earnings forecast for Hancock Jaffe Laboratories

How were Hancock Jaffe Laboratories' earnings last quarter?

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) released its quarterly earnings results on Monday, November, 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.05).
View Hancock Jaffe Laboratories' earnings history

How has Hancock Jaffe Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Hancock Jaffe Laboratories' stock was trading at $0.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HJLI shares have increased by 1,112.0% and is now trading at $6.06.
View which stocks have been most impacted by COVID-19

Who are Hancock Jaffe Laboratories' key executives?

Hancock Jaffe Laboratories' management team includes the following people:
  • Robert Andrew Berman, Chief Executive Officer & Director
  • Craig T. Glynn, Chief Financial Officer
  • Marc H. Glickman, Chief Medical Officer & Senior Vice President
  • Brian Roselauf, Director-Research & Development
  • Hamed Alavi, Vice President-Research, Development & Quality

Who are some of Hancock Jaffe Laboratories' key competitors?

What other stocks do shareholders of Hancock Jaffe Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hancock Jaffe Laboratories investors own include Amarin (AMRN), VBI Vaccines (VBIV), Bionano Genomics (BNGO), Acasti Pharma (ACST), Pfizer (PFE), Exela Technologies (XELA), Boxlight (BOXL), Purple Biotech (KTOV), Nabriva Therapeutics (NBRV) and OpGen (OPGN).

When did Hancock Jaffe Laboratories IPO?

(HJLI) raised $8 million in an initial public offering on Thursday, May 31st 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Network 1 Financial Securities served as the underwriter for the IPO and ViewTrade Securities was co-manager.

What is Hancock Jaffe Laboratories' stock symbol?

Hancock Jaffe Laboratories trades on the NASDAQ under the ticker symbol "HJLI."

How do I buy shares of Hancock Jaffe Laboratories?

Shares of HJLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hancock Jaffe Laboratories' stock price today?

One share of HJLI stock can currently be purchased for approximately $6.06.

How much money does Hancock Jaffe Laboratories make?

Hancock Jaffe Laboratories has a market capitalization of $51.53 million and generates $30,000.00 in revenue each year.

How many employees does Hancock Jaffe Laboratories have?

Hancock Jaffe Laboratories employs 12 workers across the globe.

What is Hancock Jaffe Laboratories' official website?

The official website for Hancock Jaffe Laboratories is

Where are Hancock Jaffe Laboratories' headquarters?

Hancock Jaffe Laboratories is headquartered at 70 DOPPLER, IRVINE CA, 92618.

How can I contact Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories' mailing address is 70 DOPPLER, IRVINE CA, 92618. The company can be reached via phone at (949) 261-2900.

This page was last updated on 4/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.